SELECT Trial Final Results: How Semaglutide's 20% MACE Reduction Reshapes Obesity-Related Cardiac Care
Quick Facts
How Did the SELECT Trial Design Isolate Cardiovascular Benefit From Glucose-Lowering Effects?
Previous landmark GLP-1 receptor agonist trials — including LEADER, SUSTAIN-6, and PIONEER 6 — enrolled patients with type 2 diabetes, making it impossible to separate cardiovascular protection from glycaemic improvement. The SELECT investigators deliberately required all 17,604 participants to be free of diabetes at enrollment while having confirmed atherosclerotic cardiovascular disease (prior myocardial infarction, stroke, or symptomatic peripheral artery disease). This criterion created a study population where metabolic benefit could be assessed without the confounding variable of glucose reduction.
Participants were randomised 1:1 to subcutaneous semaglutide 2.4 mg once weekly or matched placebo, with dose escalation over 16 weeks to mitigate gastrointestinal side effects. The primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke was adjudicated by an independent clinical events committee blinded to treatment assignment. By isolating a non-diabetic cohort, SELECT provided the clearest evidence to date that GLP-1 receptor agonism confers cardiovascular protection through pathways distinct from glucose homeostasis.
Which Cardiovascular Event Was Most Reduced and What Does That Imply for Atherosclerotic Plaque Stability?
When the three-point MACE endpoint was broken into individual components, non-fatal myocardial infarction demonstrated the largest relative risk reduction. While cardiovascular death and non-fatal stroke both trended in a favourable direction, the disproportionate benefit on heart attacks has drawn attention from interventional cardiologists and vascular biologists. Plaque rupture — the proximate cause of most acute myocardial infarctions — is driven by local inflammation, thin fibrous caps, and large lipid cores, all processes potentially modifiable by semaglutide's anti-inflammatory properties.
Circulating biomarker data from the trial showed that semaglutide reduced high-sensitivity C-reactive protein by roughly 40%, a magnitude comparable to statin-level anti-inflammatory effects. Reductions in interleukin-6 and other inflammatory mediators have been reported in complementary mechanistic studies. These findings align with imaging substudies of other GLP-1 receptor agonists that demonstrated reduced carotid intima-media thickness and improved endothelial function. Taken together, the data support the hypothesis that semaglutide stabilises atherosclerotic plaques, lowering the likelihood of acute coronary events beyond what weight reduction alone would predict.
How Have Cardiology Guidelines Responded to the SELECT Trial Findings?
Following the presentation of SELECT results at the 2023 American Heart Association Scientific Sessions and their publication in the New England Journal of Medicine, several guideline bodies moved swiftly. The American Heart Association and the American College of Cardiology incorporated semaglutide into their framework for secondary cardiovascular prevention in patients with overweight or obesity. The European Society of Cardiology similarly flagged GLP-1 receptor agonists as a Class IIa recommendation for cardiovascular risk reduction in this population during its 2024 guideline update cycle.
The practical implication is substantial: clinicians now have a pharmacological option for cardiovascular risk reduction that simultaneously addresses obesity — a gap that statins, antihypertensives, and antiplatelet agents do not fill. Following the FDA's March 2024 approval of the semaglutide 2.4 mg cardiovascular indication (marketed as Wegovy), prescribing patterns have shifted, with cardiologists increasingly initiating therapy alongside traditional secondary prevention agents. Insurance coverage decisions and cost-effectiveness analyses continue to evolve, but the clinical consensus is clear: SELECT has established GLP-1 receptor agonists as a new pillar of cardiometabolic care.
Frequently Asked Questions
Subgroup analyses indicated that cardiovascular risk reduction occurred across a range of weight loss outcomes. Even participants who lost relatively modest amounts of weight experienced meaningful reductions in MACE, suggesting that semaglutide's cardioprotective effects extend beyond weight loss through anti-inflammatory and vascular mechanisms.
High-intensity statin therapy typically reduces MACE by 25–35% in secondary prevention populations. The 20% relative risk reduction seen with semaglutide in SELECT is additive because most participants were already on statin therapy (approximately 90%), meaning semaglutide provides further benefit on top of optimised lipid-lowering treatment.
Pre-specified subgroup analyses showed consistent benefit across age groups, sexes, baseline BMI categories, and geographic regions. No subgroup demonstrated statistically significant harm, reinforcing the broad applicability of the findings to the enrolled population of adults with overweight or obesity and established atherosclerotic disease.
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084.
- U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. FDA News Release. March 8, 2024.
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131.